Atomo Diagnostics and Owen Mumford partner to introduce best-in-class HIV rapid testing in European markets
June 4, 2018 |
Sydney, Australia and Woodstock, England – June 2018 | Atomo Diagnostics and Owen Mumford Ltd have today announced a strategic partnership for commercialisation of innovative HIV rapid tests in European markets
- Owen Mumford acquires exclusive rights to Atomo’s HIV rapid tests for commercialisation under its Simplitude™ brand in professional use markets throughout Europe.
- AtomoRapid™ rapid diagnostic test platforms are proven to deliver a breakthrough in usability and performance at the point of care, integrating a sterile safety lancet and unique calibrated blood collection system in an easy-to-use handheld device.
The partnership sees Owen Mumford acquire exclusive rights to Atomo’s range of CE-Marked in vitro HIV rapid diagnostic tests (RDTs) for commercialisation via its established sales and distribution networks under its Simplitude ™ brand. Initially focused on professional use testing in Europe, the parties are currently exploring options to extend the agreement to cover HIV self-testing.
Although overall rates of HIV infection are lower in Europe than in Africa or Commonwealth of Independent States (CIS) countries, rates of detection are concerning. The European Centre for Disease Prevention and Control (ECDC) has estimated that one in six people living with HIV are undiagnosed. Moreover, in Europe close to half (47%) of all HIV cases are diagnosed late, with 28% of cases having advanced HIV infection (CD4 cell count <200/mm3). The proportion of those diagnosed late is over 50% in nine European countries including Italy, Greece, and Sweden.
While there is no cure for HIV infection, effective antiretroviral (ARV) drugs can effectively control the virus and help prevent transmission so that people with HIV, and those at substantial risk, can enjoy healthy, long and productive lives.
Diagnosis is thus considered key in the global fight against HIV and the convenience and prompt results offered by point-of-care tests that can be deployed in community-based settings are critical in this regard.
The new-to-market Simplitude™ HIV detects the presence or absence of HIV antibodies in a single drop of blood obtained from a fingertip. The test result can be read in minutes, which is essential for same day diagnosis and access to early treatment and care. Unlike standard, multi-component rapid test kits, Atomo’s all-in-one, multi-award winning AtomoRapid™ RDT platforms integrate necessary features and functionality in a single handheld, easy-to-use device.
“Owen Mumford is delighted to announce our new strategic partnership with Atomo Diagnostics which signals an exciting new chapter for us,” said Jarl Severn, Managing Director of Owen Mumford Ltd. “Our company has considerable expertise of medical devices and has long and established connections in the diagnostic sector. This partnership brings together two companies with reputations for excellence in medical devices and commitment to ensuring best-in-class diagnostic performance. Beyond HIV testing, we are also exploring other areas for collaboration in global markets.’
Founder and CEO of Atomo Diagnostics, John Kelly, adds, “We are extremely excited to be working with such a long-established and respected partner as Owen Mumford. This strategic partnership offers significant mutual benefits and, by leveraging Owen Mumford’s established sales network, will support the roll-out of Atomo’s HIV test devices in developed healthcare markets. Our companies have already formed a close working relationship and we are hoping to extend the scope and nature of our collaboration in the months ahead to further support the growth plans of both companies.”
Simplitude ™ HIV will be made available in European markets during 2018.